The benign prostatic hyperplasic devices market in Asia Pacific is expected to grow from US$ 484.08 million in 2022 to US$771.09 million by 2028; it is estimated to grow at a CAGR of 8.1% from 2022 to 2028.
Based on procedure type, the Asia Pacific benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period.
Based on end user, the Asia Pacific benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period.
Based on country, the Asia Pacific benign prostatic hyperplasic devices market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. In 2022, China held a larger market share. On the other side, and India is expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Asia Pacific benign prostatic hyperplasic devices market.
Asia Pacific Benign Prostatic Hyperplasic Devices Market Segmentation
The Asia Pacific benign prostatic hyperplasic devices market is segmented on the basis of product, procedure type, end user, and country. Based on product, the market is segmented into resectoscopes, urology lasers, radiofrequency ablation devices, prostatic stents, and implants. The resectoscopes segment is expected to hold the largest share of the market in 2022. On the other hand, the urology lasers segment is expected to register the highest CAGR during the forecast period.Based on procedure type, the Asia Pacific benign prostatic hyperplasic devices market is segmented into transurethral microwave therapy, transurethral resection of the prostate, transurethral needle ablation of the prostate, laser surgery, urolift surgery, and others. The transurethral resection of the prostate segment held the largest market share in 2022, and it is also expected to register the highest CAGR in the market during the forecast period.
Based on end user, the Asia Pacific benign prostatic hyperplasic devices market is segmented into hospitals, clinics, ambulatory surgical centers, and others. The hospital segment held the largest market share in 2022, while the clinics segment is expected to register the highest CAGR during the forecast period.
Based on country, the Asia Pacific benign prostatic hyperplasic devices market is segmented into China, Japan, India, Australia, South Korea, and Rest of Asia Pacific. In 2022, China held a larger market share. On the other side, and India is expected to register a higher CAGR during the forecast period.
KARL STORZ SE & Co. KG; Olympus Corporation; Boston Scientific Corporation; Teleflex Incorporated; and Richard Wolf GmbH are among the leading companies in the Asia Pacific benign prostatic hyperplasic devices market.
Table of Contents
1. Introduction
3. Research Methodology
4. Asia Pacific Benign Prostatic Hyperplasic Devices Market - Market Landscape
5. Asia Pacific Benign Prostatic Hyperplasic Devices Market - Key Market Dynamics
6. Asia Pacific Benign Prostatic Hyperplasic Devices Market Analysis
7. Asia Pacific Benign Prostatic Hyperplasic Devices Market - by Product
8. Asia Pacific Benign Prostatic Hyperplasic Devices Market - by Procedure Type
9. Asia Pacific Benign Prostatic Hyperplasic Devices Market - by End User
10. Asia Pacific Benign Prostatic Hyperplasic Devices Market - by Country Analysis
11. Asia Pacific Benign Prostatic Hyperplasic Devices Market - Industry Landscape
12. Company Profiles
13. Appendix
List of Tables
List of Figures
Companies Mentioned
- KARL STORZ SE & Co. KG
- Olympus Corporation
- Boston Scientific Corporation
- Teleflex Incorporated
- Richard Wolf GmbH
- GmbH
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 157 |
Published | October 2022 |
Forecast Period | 2022 - 2028 |
Estimated Market Value ( USD | $ 484.08 Million |
Forecasted Market Value ( USD | $ 771.09 Million |
Compound Annual Growth Rate | 8.1% |
Regions Covered | Asia Pacific |
No. of Companies Mentioned | 6 |